Huperzine A for mild-to-moderate Alzheimer's dementia
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 85 years old.
- You have been diagnosed with probable Alzheimer's disease and have had memory problems for at least a year.
- Your dementia is mild to moderate (stage 4 or 5 on the Alzheimer's disease scale).
- You have a reliable caregiver who spends at least 4 days a week and 2 hours a day with you.
- You have had at least 5 years of formal education and can complete thinking and memory tests.
- You have not used certain Alzheimer's medications like donepezil or donanemab in the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This trial tests whether huperzine A can improve hearing-related symptoms along with tinnitus (ringing) and mild cognitive (memory/thinking) problems. If you have mild-to-moderate hearing loss plus bothersome constant tinnitus and some cognitive decline, this study may help researchers see if the treatment makes a difference.
This trial tests a smaller, easier-to-swallow version of rivastigmine for people with Alzheimer's disease. It looks at whether the mini-tablet can help with memory and thinking symptoms.
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
This study tests a drug called Huperzine A, given as an injection, to see if it helps prevent or improve memory and thinking problems after a brain aneurysm is treated. It is for people who had a brain aneurysm bleed and are having surgery or a procedure to fix it soon.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Hear when a new Alzheimer Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.